Anzeige
Mehr »
Login
Samstag, 08.05.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Signifikante Entwicklungen bei Schmerz und COVID!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PTNF ISIN: US88875G1013 Ticker-Symbol: RTRA 
Tradegate
06.05.21
21:21 Uhr
1,950 Euro
-0,170
-8,02 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TIZIANA LIFE SCIENCES PLC ADR Chart 1 Jahr
5-Tage-Chart
TIZIANA LIFE SCIENCES PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
1,9202,02007.05.

Aktuelle News zur TIZIANA LIFE SCIENCES PLC ADR Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
TIZIANA LIFE SCIENCES PLC ADR Aktie jetzt für 0€ handeln
FrTiziana Life Sci PLC: TLSA interview on Bloomberg TV on 8th May 2021-
FrTiziana Life Sciences Plc: Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report161NEW YORK and LONDON, May 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious...
► Artikel lesen
MiTiziana Life Sciences plc - 6-K, Report of foreign issuer3
MiTiziana inks deal with Takanawa for development of Milciclib in Asia for liver cancer-
MiTiziana Life Sci PLC: TLSA Strategic Initiative with Takanawa Japan K.K.1
MiTiziana Life Sciences Plc: Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellular Carcin164Objective of this partnership with Takanawa Japan K.K., Pharma Team, is to identify a strategic partner in Japan for further development of Milciclib either alone or in combination with a tyrosine kinase...
► Artikel lesen
27.04.Tiziana Life Sci PLC: B. Riley Virtual Neuroscience Investor Conference-
27.04.Tiziana Life Sciences Plc: Tiziana Life Sciences to participate in a Fireside Chat on 28 April 2021 at 10:30 a.m. EDT155NEW YORK and LONDON, April 27, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA/ LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for...
► Artikel lesen
13.04.Tiziana Life Sciences plans to list Accustem Sciences on Nasdaq6
13.04.Tiziana Life Sciences intends to list Accustem Sciences in the U.S.-
13.04.Tiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S.2
13.04.Tiziana Life Sciences Plc: Tiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S.188NEW YORK and LONDON, April 13, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ:TLSA; LSE: TILS), today announced that its former subsidiary, Accustem Sciences Limited ("Accustem"), intends...
► Artikel lesen
13.04.Tiziana Life Sciences plc - 6-K, Report of foreign issuer1
13.04.Tiziana Life Sci PLC: Tiziana Announces Plans to List Accustem in US1
12.04.OTIC, HLIT, VNET and TLSA among after-hours movers5
30.03.IN BRIEF: Tiziana plans phase II trials for nasal Covid-19 treatment5
30.03.Tiziana To Treat Multiple Sclerosis Patient With Nasal Administration of Foralumab-
30.03.Tiziana Life Sci PLC: FDA Allows Foralumab Treatment for a SPMS Patient2
30.03.Tiziana Life Sciences Plc: Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Exp210NEW YORK and LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics...
► Artikel lesen
30.03.Tiziana Life Sciences Plc: Tiziana Life Sciences plc: Accustem Update212NEW YORK and LONDON, March 30, 2021. Once the SEC has approved the Form 20-F (or it becomes effective), the final aspect of the distribution will be complete and Accustem will be an entirely separate...
► Artikel lesen
Seite:  Weiter >>
141 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1